ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0571

Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study

Sabrina Hamroun1, Laure Gossec2, Serge Perrot3, Maxime Dougados4 and Anna Molto5, 1Cochin University Hospital, Paris, Ile-de-France, France, 2Sorbonne Université, Paris, France, 3Paris Dauphine University, Paris, France, 4Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 5Groupe Hospitalier Cochin, AP-HP, Paris, France

Meeting: ACR Convergence 2024

Keywords: Disease Activity, gender, Patient reported outcomes, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: There are several tools for assessing disease activity in spondyloarthritis (SpA). The literature reveals gender differences, with unfavorable Patient Reported Outcomes in women compared with men. The aim of this study was to evaluate the influence of gender on the tools used to assess disease activity in axial SpA, and their ability to discriminate Patient Acceptable Symptom State (PASS), depending on gender.

Methods: This is an ancillary analysis of the Predict-SpA cross-sectional study (NCT03039088). Patients had a diagnosis of axial SpA according to their rheumatologist and an indication to start a TNF inhibitor. Disease activity was assessed prior to initiation of treatment using BASDAI, ASDAS-CRP scores, patient and physician global assessment of disease activity. Patients were also asked to rate whether their health status in relation to axial SpA was considered acceptable or unacceptable (PASS, yes/no). To analyse the ability of disease activity assessment tools to discriminate PASS, we calculated a standardized mean difference (SMD) for each tool in the total population, in men and in women.

Results: Of the 526 patients included in Predict-SpA, 522 had an available PASS and were analysed, including 279 (53.4%) men and 243 (46.6%) women. Overall, women with a PASS had comparatively lower activity scores than men with a PASS. In the overall population, the BASDAI, ASDAS-CRP and patient global assessment of disease activity performed well in discriminating PASS (SMD 1.17, 0.93 and 1.36, respectively). However, there were gender differences, with BASDAI score performing better in women than in men (SMD 1.47 and 0.94, respectively). The physician global assessment was the least discriminating tool, with no gender differences (SMD 0.75, 0.80 and 0.81 in the overall population, in men and in women, respectively).

Conclusion: The disease activity assessment tools appear to be able to discriminate PASS, apart from the physician global assessment of disease activity, in the whole population. The ASDAS-CRP performs homogeneously according to gender, which argues in its favour at the population level. As the BASDAI has a better discriminating performance in women, it could be used in studies including only women.

Supporting image 1

Table 1. Performance of disease activity assessment tools in discriminating PASS in men and women with axial SpA.

Supporting image 2

Figure 1. Disease activity scores according to PASS in men and women with axial SpA.


Disclosures: S. Hamroun: None; L. Gossec: AbbVie, 2, 5, Amgen, 2, Biogen, 5, Bristol-Myers Squibb (BMS), 2, Celltrion, 2, Eli Lilly, 2, 5, Galapagos, 2, Janssen, 2, MSD, 2, Novartis, 2, 5, Pfizer, 2, Sandoz, 2, UCB, 2, 5; S. Perrot: None; M. Dougados: AbbVie, 2, 5, 6, Eli Lilly, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB Pharma, 2, 5, 6; A. Molto: AbbVie, 2, 5, MSD, 2, 5, Pfizer, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Hamroun S, Gossec L, Perrot S, Dougados M, Molto A. Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/gender-specific-performance-of-disease-activity-assessment-tools-in-axial-spondyloarthritis-ancillary-analysis-of-the-predict-spa-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gender-specific-performance-of-disease-activity-assessment-tools-in-axial-spondyloarthritis-ancillary-analysis-of-the-predict-spa-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology